Science in China Series C: Life Sciences

, Volume 49, Issue 6, pp 567–572 | Cite as

Various tolerances to arsenic trioxide between human cortical neurons and leukemic cells

Article
Received:
Accepted:

Abstract

Arsenic trioxide (As2O3) is very effective for treatment of acute promyelocytic leukaemia (APL) but little can pass through the blood-brain-barrier (BBB), which limits its use in the prevention and treatment of central nervous system leukaemia (CNSL). Before creating a non-invasive method to help As2O3’s access, the safe and effective therapeutic concentration of As2O3 in the CNS ought to be known. The changes of apoptosis biomarkers, [Ca2+]i and PKC activity of both leukaemia cells and human cortical neurons, were monitored before and after being treated with As2O3 in vitro with laser confocal microscopy and Western blot. NSE concentration, the neuron invasive biomarker, was monitored by enzyme immunoassay (NSE-EIA). This study revealed that cortical neuron was more tolerable to As2O3 compared to NB4. 1.0 μmol / L As2O3 showed little influence on cortical neuron but effectively promoted apoptosis and induced differentiation of NB4.

Keywords

arsenicals protein kinase C neurone specific enolase 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Liu P, Han Z C. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies. Int J Hematol, 2003, 78: 32–39PubMedCrossRefGoogle Scholar
  2. 2.
    Zhou J, Meng R, Liu Y, et al. Clinical and experimental study of cardiac effects of conventional dosage arsenic trioxide in APL patients. Chin J Hematol, 2004, 25(1): 31–34Google Scholar
  3. 3.
    Ye J, Li A, Liu Q, et al. Inhibition of mitogen-activated protein enhances apoptosis induced by arsenic trioxide in human breast cancer MCF-7 cells. Clin Exp Pharmacol Physiol, 2005, 32(12): 1042–1048PubMedCrossRefGoogle Scholar
  4. 4.
    Zhou J, Meng R, Meng L, et al. Effects of arsenic trioxide on protein kinase C and cytosolic calcium in ventricular myocardium of guinea pig. Clin J Pharmacol Toxicol, 2004, 18(6): 449–452Google Scholar
  5. 5.
    Guille J G, Brian C A, Fitzer C J. Altered level of protein kinase C and Ca++-dependent protein kinases in human colon carcinoma. Cancer Res, 1987, 47: 2036–2041Google Scholar
  6. 6.
    Zhou J, Meng R, Wang Y, et al. Clinical observation and following up of two administration methods of arsenic trioxide in treatment of acute promyelocytic leukemia. Natl Med J China 2004, 84(5): 9–12Google Scholar
  7. 7.
    Meng R, Zhou J, Wang D S, et al. Study on mannitol osmotic opening blood brain barrier by peripheral intravenous infusion. J Apoplexy and Nervous Disease, 2003, 20(4): 350–352Google Scholar
  8. 8.
    Guille J G, Brian C A, Fitzer C J. Altered level of protein kinase C and Ca++-dependent protein kinases in human colon carcinoma. Cancer Res, 1987, 47: 2036–2041Google Scholar
  9. 9.
    Ishino K, Fukazawa H, Shikano M, et al. Enhancement of anchorage-independent growth of human pancreatic carcinoma MIA PaCa-2 cells by signaling from protein kinase C to mitogen-activated protein kinase. Mol Carcinog, 2002, 34: 180–186PubMedCrossRefGoogle Scholar
  10. 10.
    Harada K, Maekawa T, Abu Shama KM, et al. Translocation and down-regulation of protein kinase Calpha,-beta and gamma isoforms during ischemia-reperfusion in rat brain. J Neurochem, 1999, 72: 2556–2564PubMedCrossRefGoogle Scholar
  11. 11.
    Wu Q, Liu S, Ding Lg, et al. PKCα translocation from mitochodria to nucleus is closely related to induction of apoptosis in gastric cancer cells. Sci China Ser C-life Sci, 2002, 45(3): 237–244CrossRefGoogle Scholar
  12. 12.
    Lamers K J, Vos P, Verbeek M M, et al. Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res Bull, 2003, 61(3): 261–264PubMedCrossRefGoogle Scholar
  13. 13.
    Ebert W, Muley T, Trainer C, et al. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC. Anti Cancer Res, 2002, 22(2B): 1083–1089Google Scholar
  14. 14.
    Zhao W L, Chen S J, Shen Y, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies. Leuk Lymphoma, 2001, 42(6): 1265–1273.PubMedCrossRefGoogle Scholar
  15. 15.
    Chen Z, Wang Z Y, Chen S J. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther, 1997, 76(1–3): 141–149PubMedCrossRefGoogle Scholar
  16. 16.
    Zhou G B, Dong Y, Wang Y Y, et al. Gene product-targeting therapy: From acute promyelocyte to other types of leukemia, Sci China Ser C-Life Sci (in Chinese), 2004, 34(6): 487–500Google Scholar

Copyright information

© Science in China Press 2006

Authors and Affiliations

  1. 1.The First Hospital of Harbin Medical UniversityHarbinChina
  2. 2.Shijitan HospitalThe Ninth Clinical Medical College of Peking UniversityBeijingChina
  3. 3.Xuanwu HospitalCapital University of Medical SciencesBeijingChina

Personalised recommendations